Biotech

Inside the discoveries, personalities, and deals driving drug development. Sign up for the Readout newsletter here.

Biotech

Moderna’s record-setting IPO dives in its debut

By Damian Garde

The Readout LOUD

LISTEN: Using the word ‘cure,’ an FDA loophole, & making biotech history

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

Donald Trump & Xi Jinping
Politics

The Trump administration called this biotech VC firm a suspicious agent of China. It’s run by U.S. citizens

By Rebecca Robbins

Steve Burrill
Biotech

Legendary biotech VC Steven Burrill sentenced to 2.5 years for fraud

By Damian Garde

Biotech

Four big questions ahead of Moderna’s public debut — biotech’s biggest ever

By Damian Garde

Foundation Medicine
Biotech

For one cancer patient, biotech’s genetic test turns out to be a ‘lifesaver’

By Jonathan Saltzman — Boston Globe

Biotech

Bluebird’s gene therapy improved outcomes for patients, as push for filing gains steam

By Adam Feuerstein

Sickle and normal red blood cells
In the Lab

One to watch at ASH18: She’s 17 and she studies chronic pain in sickle cell disease

By Adam Feuerstein

Gene Therapy Sickle Cell
Biotech

Global Blood, FDA agree on fast-filing plan for new sickle cell disease drug

By Adam Feuerstein

Ovarian Tumor
Biotech

GSK buys cancer biotech Tesaro for $5.1B

By Adam Feuerstein

Harbour Bio-Med
Biotech

Pharma Valley, China’s equivalent of Kendall Square, is expanding rapidly

By Yi-Ling Liu

Biotech

Unbowed by critics, Gilead’s cancer chief pushes ahead with growth plans

By Adam Feuerstein

Adam's Take

Misfortune strikes a Bluebird patient, highlighting the safety risks involved with gene therapy

By Adam Feuerstein

Biotech

The benefit of a blood disease drug from Acceleron and Celgene debated by experts

By Adam Feuerstein

Dr. Erica Esrick and Manny Jones
Biotech

Novel gene therapy ‘switch’ for sickle cell disease shows encouraging results in pilot trial

By Adam Feuerstein

Biotech

The CRISPR’d twins controversy upended the world of science. Wall Street? Not so much

By Kate Sheridan

Biotech

FDA signs off on Editas CRISPR study on patients with a rare genetic disorder

By Damian Garde

The Readout LOUD

LISTEN: Your guide to the #CRISPRbabies controversy

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

MassNextGen
Biotech

Almost no venture capital funding goes to women. Can a pitchfest bring parity to biotech?

By Kate Sheridan

Biotech

With schizophrenia drug results, Alkermes gets much-needed good news. But insurers could pose challenge

By Adam Feuerstein

STAT SPOTLIGHT
Biotech

Startup Spotlight: Gates-backed biotech Vir starts its first clinical trial

By Kate Sheridan

Vertex
Biotech

Vertex cystic fibrosis drug combination shows strong results in pivotal clinical trials

By Adam Feuerstein

prostate cancer cells
Biotech

Loxo’s cancer drug wins a pioneering FDA approval. Now it has to find some patients

By Damian Garde

Adam's Take

Ziopharm shares are moving higher on a turnaround strategy, but is it for real? A closer look

By Adam Feuerstein

Pre-eclampsia
Biotech

New research highlights an unexpected future for RNAi-based drugs — for pregnant women

By Kate Sheridan

China flags
Biotech

Trump administration accuses China of unfairly using venture capital to acquire American biotech

By Rebecca Robbins

Aveo Pharmaceuticals
Biotech

Jury finds former Aveo CFO misled investors about kidney cancer drug

By Jonathan Saltzman — Boston Globe

Adam's Take

If biotech stock values are down, why isn’t M&A picking up?

By Adam Feuerstein

SQZ Biotech GIF
Biotech

SQZ Biotech pushes forward with its method to squeeze drugs into cells

By Kate Sheridan

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy